Harrigan PR - Search Results

1

Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection.

Chan KC, Galli RA, Montaner JS, Harrigan PR. Chan KC, et al. Among authors: harrigan pr. AIDS. 2003 May 23;17(8):1256-8. doi: 10.1097/00002030-200305230-00020. AIDS. 2003. PMID: 12819530

2

The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.

Grant M, Pardoe I, Whaley M, Montaner JS, Harrigan PR. Grant M, et al. Among authors: harrigan pr. AIDS. 2002 Jan 25;16(2):287-90. doi: 10.1097/00002030-200201250-00019. AIDS. 2002. PMID: 11807314

3

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Côté HC, et al. Among authors: harrigan pr. N Engl J Med. 2002 Mar 14;346(11):811-20. doi: 10.1056/NEJMoa012035. N Engl J Med. 2002. PMID: 11893792 Free article.

4

Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O'Shaughnessy MV, Mo T, Piaseczny M, Montaner JS, Harrigan PR. Alexander CS, et al. Among authors: harrigan pr. Antivir Ther. 2002 Mar;7(1):31-5. Antivir Ther. 2002. PMID: 12008785

5

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Among authors: harrigan pr. AIDS. 2002 Sep 27;16(14):1929-33. doi: 10.1097/00002030-200209270-00010. AIDS. 2002. PMID: 12351953

6

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.

Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Among authors: harrigan pr. AIDS. 2003 Jan 24;17(2):201-8. doi: 10.1097/00002030-200301240-00010. AIDS. 2003. PMID: 12545080

7

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: harrigan pr. AIDS. 2003 Mar 28;17(5):711-20. doi: 10.1097/00002030-200303280-00009. AIDS. 2003. PMID: 12646794

8

Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Wynhoven B, Mo T, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. Among authors: harrigan pr. Antivir Ther. 2003 Apr;8(2):91-6. Antivir Ther. 2003. PMID: 12741620

9

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

Lee N, Hogg RS, Yip B, Harrigan PR, Harris M, O'Shaughnessy MV, Montaner JS. Lee N, et al. Among authors: harrigan pr. J Infect Dis. 2003 Jul 1;188(1):137-41. doi: 10.1086/375781. Epub 2003 Jun 23. J Infect Dis. 2003. PMID: 12825182

10

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O'Shaughnessy MV, Harrigan PR. Alexander CS, et al. Among authors: harrigan pr. J Infect Dis. 2003 Aug 15;188(4):541-8. doi: 10.1086/376835. Epub 2003 Jul 29. J Infect Dis. 2003. PMID: 12898441 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters